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OBJECTIVES: Infliximab is indicated in Crohn’s disease (CD) resistant to standard
treatment (ST), but its impact on health care costs and quality-adjusted life-expec-
tancy is incompletely understood. We assessed the cost-effectiveness of episodic
(ET) and maintenance (MT) infliximab treatment in CD patients with 10-years
follow-up. METHODS: A total of 212 incident adult CD patients (age at onset
34.414.5 years, 49.4% male) were treated with antibiotics, mesalazine, corticoste-
roids, thiopurines, surgery (comprising ST) over 10-years to 2004. Eight health
states were defined by intensity of therapy in these patients. We determined
Markov transition probabilities between these states, health care costs and QALYs
in 3 month-cycles. This cohort was modeled to allow drug-refractory or pre-surgery
patients to receive infliximab: either ET in one cycle, or MT in responders for a
period of 1-year (MT-1yr) or for 10-years (MT-10 yrs). Transition probabilities of ST
were applied to patients getting IFX; the probability of continuing infliximab in MT
was set to correct for decay. Health care costs and QALYs in ET and MT were
estimated for 10-years (discounted at 3%) and compared with those of ST patients.
RESULTS: The average cost (QALYs gained) per patient over 10-years was €23,169
(6.7014) for ST; €21,691 (7.0403) for ET, €29,012 (7.0553) for MT-1yr, and €50,416
(7.2603) for MT-10 yrs. ST was associated with higher costs and lower outcomes and
was thus dominated by ET. The incremental cost-effectiveness ratios (ICERs) of
MT-1yr and MT-10 yrs over ST were €16,510/QALY gained, and €48,751/QALY
gained, respectively. When compared with ET, the ICERs of MT-1yr and MT-10 yrs
were €488,066/QALY gained, and €130,568/QALY gained, respectively. When the
infliximab price was halved these ICERs remained very high. CONCLUSIONS: ET or
MT with infliximab are either cost-saving or cost-effective when compared with
ST. However, at current drug prices, MT does not provide good value for money
when compared with ET.
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OBJECTIVES: To evaluate direct medical costs, health outcomes, and cost-effec-
tiveness of 48-week Peginterferon alpha-2a with 2nd line 2-years Entecavir
treatment versus 3 years Entecavir treatment for HBeAg-positive chronic hep-
atitis B according to the Response Guided Treatment (RGT) strategy in China.
METHODS: A Markov model was designed to evaluate the direct medical costs
and outcomes (life years and QALYs gained) of treating HBeAg-positive chronic
hepatitis B in China, with a maximum analysis time horizon of 80 years. The
model included 10 health states – Chronic hepatitis B (CHB), HBeAg seroconver-
sion, HBsAg loss, CHB with resistance, Compensated cirrhosis, Decompensated
cirrhosis, Hepatocellular carcinoma, Liver transplant, Post-liver transplant and
death. Based on the analysis of published literature, a two-round expert panel
survey was conducted among 22 hepatitis B specialists nationally to identify
clinical and utility data. From the perspective of China’s health insurance sys-
tem, cost data was calculated based on the published literature about CHB
economic burden. A discounting rate at 3% was used to discount medical costs
and health outcomes that happened at different years. A univariate sensitivity
analysis was performed to understand the key drivers and general sensitivity of
the model. RESULTS: The model results showed that the utilization of Peginter-
feron regimen can prolong1.80 QALYs (15.00 years vs. 13.20 years), compared to
the 3 years Entecavir treatment. The total cost per patient treated with Pegin-
terferon and Entecavir was RMB 163,638 yuan (US$ 25,568) and RMB 145,116
yuan (US$ 22,674), respectively. The discounted incremental cost per QALY
gained for Peginterferon regimen was RMB 10,298 yuan (US$ 1,609) (Exchange
rate: 1 US$  6.4 CNY). CONCLUSIONS: The results of the model suggest that
48-week Peginterferon alpha-2a with 2-years Entecavir treatment as 2nd line
improves health outcomes in a cost-effective manner compared with 3 years
Entecavir for the treatment of HBeAg-positive chronic hepatitis B in China.
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OBJECTIVES: To estimate the cost-effectiveness of telaprevir in combination
with peginterferon alpha and ribavirin (PR) compared to PR alone in previously
treated patients. METHODS: A cost-utility analysis based on previously pub-
lished Markov models for chronic hepatitis C was used. Efficacy in the model
was derived from results of randomized placebo controlled trial (REALIZE). RE-
ALIZE compared telaprevir in combination with PR to PR alone in patients who
failed previous treatment. The trial showed significantly higher response rates
in the telaprevir patient cohort. Utility values corresponding to each health
state in the model were obtained from a NICE Health technology Assessment
and were combined with data from REALIZE. Local cost data sources were from
published price lists, clinical guidelines, product labels and expert opinion (DEL-
PHI panel). The effectiveness was measured in quality-adjusted life years
(QALY). Time horizon was set at lifelong (100 years of age or till patient dies) and
a payers’ perspective was adopted. Discount rate was 5% per year for both costs
and effects according to actual Ministry of Health guidelines for health eco-
nomic evaluation. Both one-way and probabilistic sensitivity analyses were
performed. RESULTS: Incremental cost effectiveness ratio (ICER) for telaprevir
in combination with PR compared to PR alone was 14 209 €/1 QALY. Costs for one
life year saved (LYS) were 20 026 €/1 LYS. Model was most sensitive to price of
telaprevir in deterministic sensitivity analysis. In probabilistic sensitivity anal-
ysis 75 % of simulations were below 26 650 €/1 QALY. CONCLUSIONS: Telaprevir
in combination with PR is a cost-effective compared to PR alone for the treat-
ment of chronic hepatitis C in patient who failed previous treatment with PR in
a Slovakian health care system.
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OBJECTIVES: Linaclotide is a novel once daily, orally delivered peptide that acts on
all key IBS-C symptoms. The aim of this analysis was to estimate the daily cost that
would result in linaclotide being considered cost-effective in the UK, given differ-
ent levels of willingness–to-pay (WTP).METHODS:A within-trial analysis was used
to estimate the economically justifiable price from a payer perspective in the UK
using patient-level data from a 26-week Phase III, randomized, double-blind trial of
linaclotide 290g daily (n401) versus placebo (n403) in IBS-C patients (modified
Rome II criteria). EQ-5D data was collected at randomization and each subsequent
visit. The UK valuation of the EQ-5D was applied to the raw data to estimate the
utility for each patient. Missing data were interpolated using the last-observation-
carried-forward (LOCF) method. The WTP was varied from £15,000-£20,000/QALY.
The only cost considered was that of linaclotide; total cost of treatment was
weighted by compliance. Resource use was assumed to be equal between arms.
Bootstrapping was performed to account for uncertainty. A scenario analysis was
conducted using data from a 12-week linaclotide trial in a similar population.
RESULTS: Patients treated with linaclotide gained 0.016 QALYs over the 26-week
trial compared with patients in the placebo arm. At WTP thresholds of £15,000-
£20,000/QALY linaclotide could be cost-effective at a price of £1.30-£1.70. Over 75%
of the bootstrap estimates fell below a willingness-to-pay threshold of £20,000/
QALY. The method of addressing missing data had minimal impact on the ICER. In
the scenario analysis, the QALY gain for patients treated with linaclotide was even
greater, thus a price of £2.00-£2.65 may result in linaclotide being considered cost-
effective at thresholds of £15,000-£20,000/QALY. CONCLUSIONS: The base case
analysis showed linaclotide could be cost-effective at a price of up to £1.70/day in
the UK setting using conservative assumptions.
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OBJECTIVES: Irritable bowel syndrome with constipation (IBS-C) can decrease
work productivity and increase activity impairment, resulting in a substantial
economic burden for patients and employers. Linaclotide, a minimally-ab-
sorbed guanylate cyclase C agonist (GCCA), significantly improved abdominal
and bowel symptoms in 2 Phase 3 IBS-C trials. We evaluated the linaclotide
treatment effect on work productivity and activity impairment in IBS-C
patients. METHODS: In 2 Phase 3 trials, 1602 adults with IBS-C (modified Rome II
criteria) were randomized to oral linaclotide 290 g once daily or placebo. The
self-administered 6-item Work Productivity and Activity Impairment question-
naire for IBS-C (WPAI:IBS-C) was used to evaluate IBS-C symptom-related ab-
senteeism (work hours missed), presenteeism (degree symptoms affected work
productivity), overall work productivity loss (absenteeismpresenteeism) and
daily activity impairment (degree symptoms affected activities) over the previ-
ous week. Using pooled intent-to-treat data, changes in WPAI:IBS-C scores from
baseline to Weeks 4, 8, and 12 were assessed by analysis of covariance and
represented as percentages (higher percentagegreater productivity loss and
activity impairment). Absenteeism, presenteeism and work productivity as-
sessments included employed patients only. RESULTS: Compared to placebo,
linaclotide significantly reduced presenteeism, overall work productivity loss
and daily activity impairment, and numerically decreased absenteeism, at
Weeks 4, 8 and 12. Mean changes from baseline to Week-12 for linaclotide and
placebo, and the corresponding treatment effect (LS-means difference between
linaclotide and placebo, shown as “	”), respectively, were: presenteeism, -18.4%
and -13.1% (	-5.2, P0.0001); overall work productivity loss, -19.4% and -13.0%
(	-6.1, P0.0001); daily activity impairment, -19.9% and -15.2%(	-4.7,
P0.0001); absenteeism, -1.6% and -0.9% (	-0.5, P0.311). Assuming a 40-hour
work week, linaclotide reduced overall work productivity loss by 1.6-2.4
hours/week. CONCLUSIONS: Linaclotide significantly reduced presenteeism,
overall work productivity loss and daily activity impairment for IBS-C patients
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